Summary of Study ST000063

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000059. The data can be accessed directly via it's Project DOI: 10.21228/M8V88F This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files (Contains raw data)
Study IDST000063
Study TitleBiomarkers for Depression in Human Cerebrospinal Fluid in a Population Sample
Study Typebiomarker study
Study SummaryThis West Coast Metabolomics Center pilot and feasibility project was granted to Roel Ophoff (UC Los Angeles ) and Steve Horwath (UC Los Angeles ) . Major depressive disorder (MDD) is one of the most debilitating disorders in the United States with a 12-month prevalence of 6.7% in the adult population. The disorder affects millions of Americans daily and is a major health concern with enormous economic cost the society at large. Criteria for MDD diagnosis and treatment are based on various signs and symptoms not always fitting into strict diagnostic categories such as DSM-IV. Despite various known risk factors (such as family history, age, and gender), biological markers supporting diagnosis or prediction of MDD are unavailable. We have collected cerebrospinal fluid (CSF) and peripheral blood of more than 600 subjects from the general population. For each of the participants we also obtained biometric information as well as behavioral trait measures. One of the measures is the Beck Depression Inventory (BDI), a well-established questionnaire for measuring severity of depression. Based on the BDI, roughly 5% of participants suffer from severe depressive symptoms while most of these subjects are not under treatment or receiving any medication for depression   In the current investigation, untargeted analysis of primary metabolites was conducted on age and gender matched human cerebrospinal fluid (CSF) and plasma from subjects suffering with MDD ( n=50) and control subjects (n=50). Subjects were diagnosed as having MDD based on the Beck Depression Inventory. The primary objectives of this study were to 1) identify metabolites which discriminate between subjects with and without depression symptoms in the CSF and plasma and 2) how changes correlate between CSF and plasma. 
Institute
University of California, Davis
DepartmentGenome and Biomedical Sciences Facility
LaboratoryWCMC Metabolomics Core
Last NameFiehn
First NameOliver
Address1315 Genome and Biomedical Sciences Facility 451 Health Sciences Drive Davis, CA 95616
Emailofiehn@ucdavis.edu
Phone(530) 754-8258
Submit Date2014-06-11
Num Groups3
Total Subjects105
Study Comments2014-03-03 13:37:37.766
Raw Data AvailableYes
Raw Data File Type(s)cdf
Uploaded File Size4.5 G
Analysis Type DetailGC-MS
Release Date2014-07-11
Release Version1
Oliver Fiehn Oliver Fiehn
https://dx.doi.org/10.21228/M8V88F
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:

Project:

Project ID:PR000059
Project DOI:doi: 10.21228/M8V88F
Project Title:Biomarkers for Depression in CSF and Plasma in a Population Sample
Project Type:biomarker study
Project Summary:This West Coast Metabolomics Center pilot and feasibility project was granted to Roel Ophoff (UC Los Angeles) and Steve Horwath (UC Los Angeles). Major depressive disorder (MDD) is one of the most debilitating disorders in the United States with a 12-month prevalence of 6.7% in the adult population. The disorder affects millions of Americans daily and is a major health concern with enormous economic cost the society at large. Criteria for MDD diagnosis and treatment are based on various signs and symptoms not always fitting into strict diagnostic categories such as DSM-IV. Despite various known risk factors (such as family history, age, and gender), biological markers supporting diagnosis or prediction of MDD are unavailable. We have collected cerebrospinal fluid (CSF) and peripheral blood of more than 600 subjects from the general population. For each of the participants we also obtained biometric information as well as behavioral trait measures. One of the measures is the Beck Depression Inventory (BDI), a well-established questionnaire for measuring severity of depression. Based on the BDI, roughly 5% of participants suffer from severe depressive symptoms while most of these subjects are not under treatment or receiving any medication for depression In the current investigation, untargeted analysis of primary metabolites was conducted on age and gender matched human cerebrospinal fluid (CSF) and plasma from subjects suffering with MDD ( n=50) and control subjects (n=50). Subjects were diagnosed as having MDD based on the Beck Depression Inventory. The primary objectives of this study were to 1) identify metabolites which discriminate between subjects with and without depression symptoms in the CSF and plasma and 2) how changes correlate between CSF and plasma.
Institute:University of California, Davis
Department:Genome and Biomedical Sciences Facility
Laboratory:WCMC Metabolomics Core
Last Name:Fiehn
First Name:Oliver
Address:1315 Genome and Biomedical Sciences Facility,451 Health Sciences Drive, Davis, CA 95616
Email:ofiehn@ucdavis.edu
Phone:(530) 754-8258
Funding Source:NIH U24DK097154

Subject:

Subject ID:SU000082
Subject Type:Human
Subject Species:Homo sapiens
Taxonomy ID:9606
Species Group:Mammals

Factors:

Subject type: Human; Subject species: Homo sapiens (Factor headings shown in green)

mb_sample_id local_sample_id Source
SA003341 140318ajlsa13_1Group 1 - Score 0
SA003342 140317ajlsa13_1Group 1 - Score 0
SA003343 140319ajlsa05_2Group 1 - Score 0
SA003344 140319ajlsa01_2Group 1 - Score 0
SA003345 140317ajlsa38_1Group 1 - Score 0
SA003346 140317ajlsa24_1Group 1 - Score 0
SA003347 140318ajlsa14_1Group 1 - Score 0
SA003348 140318ajlsa21_1Group 1 - Score 0
SA003349 140318ajlsa37_4Group 1 - Score 0
SA003350 140318ajlsa16_1Group 1 - Score 0
SA003351 140317ajlsa20_1Group 1 - Score 0
SA003352 140318ajlsa06_1Group 1 - Score 0
SA003353 140318ajlsa31_4Group 1 - Score 0
SA003354 140318ajlsa27_1Group 1 - Score 0
SA003355 140317ajlsa11_1Group 1 - Score 0
SA003356 140318ajlsa30_1Group 1 - Score 0
SA003357 140317ajlsa18_1Group 1 - Score 0
SA003358 140317ajlsa31_1Group 1 - Score 0
SA003359 140317ajlsa50_1Group 1 - Score 0
SA003360 140318ajlsa08_1Group 1 - Score 0
SA003361 140318ajlsa34_4Group 1 - Score 0
SA003362 140318ajlsa44_3Group 1 - Score 0
SA003363 140317ajlsa08_1Group 1 - Score 0
SA003364 140318ajlsa49_3Group 1 - Score 0
SA003365 140318ajlsa33_4Group 1 - Score 0
SA003366 140318ajlsa32_4Group 1 - Score 0
SA003367 140318ajlsa48_3Group 1 - Score 0
SA003368 140318ajlsa24_1Group 1 - Score 0
SA003369 140317ajlsa09_1Group 1 - Score 0
SA003370 140317ajlsa23_1Group 1 - Score 0
SA003371 140317ajlsa33_1Group 1 - Score 0
SA003372 140318ajlsa20_1Group 1 - Score 0
SA003373 140318ajlsa01_2Group 1 - Score 0
SA003374 140317ajlsa42_1Group 1 - Score 0
SA003375 140318ajlsa47_3Group 1 - Score 0
SA003376 140317ajlsa28_1Group 1 - Score 0
SA003377 140317ajlsa10_1Group 1 - Score 0
SA003378 140318ajlsa03_1Group 1 - Score 0
SA003379 140319ajlsa03_2Group 1 - Score 0
SA003380 140317ajlsa01_1Group 1 - Score 0
SA003381 140318ajlsa41_3Group 1 - Score 0
SA003382 140317ajlsa04_1Group 1 - Score 0
SA003383 140317ajlsa32_1Group 1 - Score 0
SA003384 140317ajlsa49_1Group 1 - Score 0
SA003385 140318ajlsa36_4Group 1 - Score 0
SA003386 140318ajlsa28_1Group 1 - Score 0
SA003387 140317ajlsa41_1Group 1 - Score 0
SA003388 140319ajlsa04_2Group 1 - Score 0
SA003389 140317ajlsa36_1Group 2 - Score 50
SA003390 140318ajlsa42_3Group 2 - Score 50
SA003391 140317ajlsa19_1Group 2 - Score 50
SA003392 140317ajlsa21_1Group 2 - Score 50
SA003393 140317ajlsa03_1Group 2 - Score 50
SA003394 140318ajlsa43_3Group 2 - Score 50
SA003395 140317ajlsa29_1Group 2 - Score 50
SA003396 140317ajlsa48_1Group 2 - Score 50
SA003397 140318ajlsa40_4Group 2 - Score 50
SA003398 140318ajlsa26_1Group 2 - Score 50
SA003399 140318ajlsa07_1Group 2 - Score 50
SA003400 140317ajlsa43_1Group 2 - Score 50
SA003401 140318ajlsa50_3Group 2 - Score 50
SA003402 140317ajlsa26_1Group 2 - Score 50
SA003403 140317ajlsa27_1Group 2 - Score 50
SA003404 140317ajlsa17_1Group 2 - Score 50
SA003405 140317ajlsa30_1Group 2 - Score 50
SA003406 140318ajlsa25_1Group 2 - Score 50
SA003407 140317ajlsa25_1Group 2 - Score 50
SA003408 140318ajlsa15_1Group 2 - Score 50
SA003409 140318ajlsa12_1Group 2 - Score 50
SA003410 140317ajlsa47_1Group 2 - Score 50
SA003411 140318ajlsa39_4Group 2 - Score 50
SA003412 140317ajlsa45_1Group 2 - Score 50
SA003413 140318ajlsa46_3Group 2 - Score 50
SA003414 140317ajlsa12_1Group 2 - Score 50
SA003415 140317ajlsa06_1Group 2 - Score 50
SA003416 140318ajlsa35_4Group 2 - Score 50
SA003417 140317ajlsa39_1Group 2 - Score 50
SA003418 140317ajlsa35_1Group 2 - Score 50
SA003419 140317ajlsa22_1Group 2 - Score 50
SA003420 140319ajlsa02_2Group 2 - Score 50
SA003421 140318ajlsa04_1Group 2 - Score 50
SA003422 140317ajlsa14_1Group 2 - Score 50
SA003423 140318ajlsa17_1Group 2 - Score 50
SA003424 140318ajlsa11_1Group 2 - Score 50
SA003425 140318ajlsa02_1Group 2 - Score 50
SA003426 140317ajlsa46_1Group 2 - Score 50
SA003427 140318ajlsa09_1Group 2 - Score 50
SA003428 140318ajlsa22_1Group 2 - Score 50
SA003429 140317ajlsa34_1Group 2 - Score 50
SA003430 140318ajlsa45_3Group 2 - Score 50
SA003431 140317ajlsa02_1Group 2 - Score 50
SA003432 140318ajlsa10_1Group 2 - Score 50
SA003433 140317ajlsa16_1Group 2 - Score 50
SA003434 140317ajlsa37_1Group 2 - Score 50
SA003435 140317ajlsa07_1Group 2 - Score 50
SA003436 140317ajlsa05_1Group 2 - Score 50
SA003437 140318ajlsa29_1Group 2 - Score 50
Showing results 1 to 97 of 97

Collection:

Collection ID:CO000065
Collection Summary:-
Sample Type:Cerebrospinal fluid

Treatment:

Treatment ID:TR000083

Sample Preparation:

Sampleprep ID:SP000078
Sampleprep Summary:-
Sampleprep Protocol Filename:CSF_Extraction_Protocol_Primary_Metabolites.docx
Sample Spiking:FAMEs

Combined analysis:

Analysis ID AN000101
Analysis type MS
Chromatography type GC
Chromatography system Agilent 6890N
Column Restek Corporation Rtx-5Sil MS
MS Type EI
MS instrument type GC-TOF
MS instrument name Leco GC-TOF
Ion Mode POSITIVE
Units Peak area

Chromatography:

Chromatography ID:CH000069
Methods Filename:Data_Dictionary_Fiehn_laboratory_GCTOF_MS_primary_metabolism_10-15-2013_general.pdf
Instrument Name:Agilent 6890N
Column Name:Restek Corporation Rtx-5Sil MS
Column Pressure:7.7 PSI (initial condition)
Column Temperature:50 - 330C
Flow Rate:1 ml/min
Injection Temperature:50C ramped to 250C by 12C/s
Sample Injection:0.5l
Oven Temperature:50C for 1 min, then ramped at 20C/min to 330C, held constant for 5 min
Transferline Temperature:230C
Washing Buffer:Ethyl Acetate
Sample Loop Size:30 m length x 0.25 mm internal diameter
Randomization Order:Excel generated
Chromatography Type:GC

MS:

MS ID:MS000077
Analysis ID:AN000101
Instrument Name:Leco GC-TOF
Instrument Type:GC-TOF
MS Type:EI
Ion Mode:POSITIVE
Ion Source Temperature:250°C
Ionization Energy:70eV
Mass Accuracy:Nominal
Source Temperature:250°C
Scanning Range:80-500 Da
Acquisition Parameters File:Data_Dictionary_Fiehn_laboratory_GCTOF_MS_primary_metabolism_10-15-2013_general.pdf
Processing Parameters File:Data_Dictionary_Fiehn_laboratory_GCTOF_MS_primary_metabolism_10-15-2013_general.pdf
  logo